 Corey Lyon
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 167 | 1.490 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 130 | 1.280 |
Why?
| | Hypertension | 3 | 2021 | 842 | 1.110 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 53 | 1.030 |
Why?
| | Medical Staff | 2 | 2022 | 11 | 1.020 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 222 | 0.930 |
Why?
| | Sphygmomanometers | 1 | 2021 | 7 | 0.910 |
Why?
| | Insulin, Isophane | 1 | 2021 | 15 | 0.900 |
Why?
| | Automation | 1 | 2021 | 56 | 0.900 |
Why?
| | Employment | 1 | 2022 | 110 | 0.890 |
Why?
| | Insulin Glargine | 1 | 2021 | 54 | 0.870 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 90 | 0.870 |
Why?
| | Preventive Health Services | 1 | 2022 | 98 | 0.860 |
Why?
| | Aspirin | 2 | 2020 | 239 | 0.860 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 11 | 0.840 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 14 | 0.830 |
Why?
| | Ganglion Cysts | 1 | 2020 | 9 | 0.820 |
Why?
| | Papillomaviridae | 1 | 2020 | 92 | 0.820 |
Why?
| | Wrist | 1 | 2020 | 27 | 0.810 |
Why?
| | Spironolactone | 1 | 2019 | 29 | 0.780 |
Why?
| | Memory | 1 | 2021 | 211 | 0.770 |
Why?
| | Diuretics | 1 | 2019 | 56 | 0.770 |
Why?
| | Probiotics | 1 | 2019 | 32 | 0.770 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 229 | 0.760 |
Why?
| | Ketorolac | 1 | 2019 | 15 | 0.760 |
Why?
| | Glucosamine | 1 | 2018 | 6 | 0.760 |
Why?
| | Acute Pain | 1 | 2019 | 24 | 0.750 |
Why?
| | Papillomavirus Infections | 1 | 2020 | 147 | 0.750 |
Why?
| | Erythromycin | 1 | 2018 | 17 | 0.740 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 5 | 0.740 |
Why?
| | Testosterone | 1 | 2021 | 227 | 0.740 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2020 | 150 | 0.730 |
Why?
| | Sweating | 1 | 2018 | 11 | 0.730 |
Why?
| | Ureteral Calculi | 1 | 2018 | 8 | 0.720 |
Why?
| | Viscosupplements | 1 | 2018 | 8 | 0.720 |
Why?
| | Hot Flashes | 1 | 2018 | 50 | 0.700 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 61 | 0.700 |
Why?
| | Musculoskeletal System | 1 | 2018 | 26 | 0.700 |
Why?
| | Hypoglycemia | 1 | 2021 | 280 | 0.700 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 30 | 0.670 |
Why?
| | Glucocorticoids | 2 | 2018 | 376 | 0.670 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 130 | 0.660 |
Why?
| | Family Practice | 2 | 2018 | 345 | 0.660 |
Why?
| | Labor, Obstetric | 1 | 2017 | 40 | 0.660 |
Why?
| | Analgesics | 1 | 2018 | 113 | 0.660 |
Why?
| | Humans | 50 | 2022 | 128242 | 0.660 |
Why?
| | Warfarin | 1 | 2017 | 106 | 0.660 |
Why?
| | Melatonin | 1 | 2017 | 77 | 0.650 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 401 | 0.650 |
Why?
| | Job Satisfaction | 1 | 2018 | 126 | 0.650 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1104 | 0.650 |
Why?
| | Migraine Disorders | 1 | 2017 | 55 | 0.650 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 100 | 0.650 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 170 | 0.640 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 148 | 0.630 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 14 | 0.630 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 73 | 0.620 |
Why?
| | Methylprednisolone | 1 | 2016 | 61 | 0.620 |
Why?
| | Menopause | 1 | 2018 | 194 | 0.610 |
Why?
| | Patient Care Team | 2 | 2018 | 352 | 0.600 |
Why?
| | Mass Screening | 2 | 2022 | 778 | 0.590 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 1416 | 0.580 |
Why?
| | Exercise Therapy | 1 | 2018 | 244 | 0.570 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 337 | 0.550 |
Why?
| | Antioxidants | 1 | 2017 | 399 | 0.540 |
Why?
| | Anticoagulants | 1 | 2017 | 385 | 0.540 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 256 | 0.540 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 1211 | 0.510 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 901 | 0.430 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 947 | 0.420 |
Why?
| | Depression | 1 | 2017 | 825 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2019 | 807 | 0.400 |
Why?
| | Aged | 9 | 2021 | 14374 | 0.390 |
Why?
| | Aged, 80 and over | 6 | 2021 | 4819 | 0.380 |
Why?
| | Treatment Outcome | 7 | 2021 | 6403 | 0.370 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 102 | 0.360 |
Why?
| | Organizational Innovation | 2 | 2019 | 103 | 0.340 |
Why?
| | Middle Aged | 10 | 2021 | 20385 | 0.330 |
Why?
| | Abdomen, Acute | 1 | 2006 | 15 | 0.330 |
Why?
| | Azithromycin | 2 | 2018 | 61 | 0.330 |
Why?
| | Pain Measurement | 2 | 2019 | 392 | 0.310 |
Why?
| | Enuresis | 1 | 2005 | 2 | 0.310 |
Why?
| | Renal Agents | 1 | 2005 | 4 | 0.310 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 10 | 0.310 |
Why?
| | Female | 23 | 2021 | 92196 | 0.310 |
Why?
| | Engineering | 11 | 2018 | 47370 | 0.290 |
Why?
| | Social Responsibility | 11 | 2018 | 47385 | 0.290 |
Why?
| | Attitude | 11 | 2018 | 47516 | 0.290 |
Why?
| | Students | 11 | 2018 | 47688 | 0.290 |
Why?
| | Pregnancy | 3 | 2020 | 3839 | 0.280 |
Why?
| | Age Factors | 2 | 2022 | 2277 | 0.270 |
Why?
| | Adult | 18 | 2021 | 70001 | 0.260 |
Why?
| | United States | 4 | 2022 | 8885 | 0.250 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 523 | 0.240 |
Why?
| | Occult Blood | 1 | 2022 | 17 | 0.240 |
Why?
| | Male | 19 | 2021 | 90667 | 0.220 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.220 |
Why?
| | Fish Oils | 1 | 2020 | 22 | 0.220 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 29 | 0.220 |
Why?
| | Labor Stage, Second | 1 | 2020 | 4 | 0.210 |
Why?
| | Colonoscopy | 1 | 2022 | 137 | 0.210 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 49 | 0.210 |
Why?
| | Hormone Replacement Therapy | 1 | 2021 | 68 | 0.210 |
Why?
| | Primary Health Care | 2 | 2019 | 1058 | 0.210 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 66 | 0.210 |
Why?
| | Systems Integration | 1 | 2018 | 40 | 0.190 |
Why?
| | Clostridium Infections | 1 | 2019 | 37 | 0.190 |
Why?
| | Ticlopidine | 1 | 2019 | 54 | 0.190 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 19 | 0.190 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.190 |
Why?
| | Patients | 1 | 2019 | 104 | 0.180 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 80 | 0.180 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 9 | 0.180 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 71 | 0.180 |
Why?
| | Primary Prevention | 1 | 2020 | 158 | 0.180 |
Why?
| | Netherlands | 1 | 2018 | 49 | 0.180 |
Why?
| | Arthralgia | 1 | 2018 | 33 | 0.180 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 86 | 0.180 |
Why?
| | Visual Analog Scale | 1 | 2018 | 21 | 0.180 |
Why?
| | Citalopram | 1 | 2018 | 19 | 0.180 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 27 | 0.180 |
Why?
| | Yoga | 1 | 2018 | 17 | 0.180 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 31 | 0.180 |
Why?
| | Patient Education as Topic | 1 | 2022 | 544 | 0.180 |
Why?
| | Burnout, Professional | 2 | 2019 | 194 | 0.170 |
Why?
| | Dietary Supplements | 1 | 2020 | 306 | 0.170 |
Why?
| | Recurrence | 1 | 2020 | 719 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 284 | 0.170 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 157 | 0.170 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 101 | 0.170 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.170 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 25 | 0.170 |
Why?
| | Regression Analysis | 1 | 2019 | 813 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1588 | 0.160 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 46 | 0.160 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 29 | 0.160 |
Why?
| | Hemorrhage | 1 | 2020 | 415 | 0.160 |
Why?
| | Surveys and Questionnaires | 12 | 2018 | 50539 | 0.160 |
Why?
| | Exanthema | 1 | 2016 | 49 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 280 | 0.160 |
Why?
| | Young Adult | 12 | 2018 | 55149 | 0.160 |
Why?
| | Psychiatry | 1 | 2018 | 128 | 0.160 |
Why?
| | Prednisone | 1 | 2016 | 172 | 0.160 |
Why?
| | Administration, Oral | 1 | 2018 | 588 | 0.150 |
Why?
| | Injections | 1 | 2016 | 110 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 113 | 0.150 |
Why?
| | Pain Management | 1 | 2018 | 204 | 0.150 |
Why?
| | Acute Disease | 1 | 2018 | 721 | 0.150 |
Why?
| | Health Status | 1 | 2020 | 557 | 0.150 |
Why?
| | Double-Blind Method | 1 | 2018 | 1191 | 0.150 |
Why?
| | Achilles Tendon | 1 | 2015 | 28 | 0.150 |
Why?
| | Quality of Health Care | 1 | 2019 | 470 | 0.150 |
Why?
| | Sulfonamides | 1 | 2018 | 331 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2020 | 558 | 0.140 |
Why?
| | Socialization | 11 | 2018 | 47368 | 0.140 |
Why?
| | Interviews as Topic | 11 | 2018 | 47819 | 0.140 |
Why?
| | Tendon Injuries | 1 | 2015 | 57 | 0.140 |
Why?
| | Gestational Age | 1 | 2017 | 550 | 0.140 |
Why?
| | Curriculum | 11 | 2018 | 47915 | 0.140 |
Why?
| | Longitudinal Studies | 11 | 2018 | 49312 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 730 | 0.140 |
Why?
| | Psychometrics | 1 | 2017 | 465 | 0.130 |
Why?
| | Metformin | 1 | 2017 | 214 | 0.130 |
Why?
| | Adolescent | 11 | 2018 | 60563 | 0.130 |
Why?
| | Pain | 1 | 2018 | 556 | 0.120 |
Why?
| | Telemedicine | 1 | 2018 | 390 | 0.120 |
Why?
| | Colorado | 2 | 2019 | 3230 | 0.120 |
Why?
| | Mental Disorders | 1 | 2018 | 679 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 714 | 0.110 |
Why?
| | Time Factors | 1 | 2020 | 5005 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1229 | 0.100 |
Why?
| | Prospective Studies | 1 | 2018 | 4425 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 181 | 0.070 |
Why?
| | Behavior Therapy | 1 | 2005 | 166 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 996 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 721 | 0.060 |
Why?
| | Dermoscopy | 1 | 2020 | 9 | 0.050 |
Why?
| | Long-Term Care | 1 | 2019 | 53 | 0.050 |
Why?
| | Models, Organizational | 1 | 2019 | 104 | 0.050 |
Why?
| | Glycated Hemoglobin A | 1 | 2022 | 597 | 0.050 |
Why?
| | Workflow | 1 | 2018 | 84 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 141 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 561 | 0.040 |
Why?
| | Skin | 1 | 2020 | 486 | 0.040 |
Why?
| | Survival Analysis | 1 | 2019 | 981 | 0.040 |
Why?
| | Rupture | 1 | 2015 | 66 | 0.040 |
Why?
| | Mental Health Services | 1 | 2018 | 235 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 349 | 0.040 |
Why?
| | Comorbidity | 1 | 2018 | 1141 | 0.030 |
Why?
| | Blood Glucose | 1 | 2022 | 1365 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 1722 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 2491 | 0.030 |
Why?
| | Quality Improvement | 1 | 2018 | 665 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 2143 | 0.030 |
Why?
| | Blood Pressure | 1 | 2016 | 1234 | 0.030 |
Why?
| | Child | 1 | 2005 | 12453 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 6441 | 0.020 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|